Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations

Author:

Gao Rachel Y.,Riley Christine M.,Toth Evan,Blair Rebecca H.,Gerold Megan N.,McCormick Caitlin,Taylor Amber W.,Hu Tianjing,Rowlen Kathy L.,Dawson Erica D.

Abstract

ABSTRACTThe COVID-19 pandemic highlighted mRNA as a promising platform for vaccines and therapeutics. Many of the analytical tools used to characterize the critical quality attributes of mRNA are inherently singleplex and are not necessarily optimal from a labor and cost perspective. Here we demonstrate feasibility of a multiplexed platform (VaxArray) for efficient identity verification and concentration determination for both monovalent and multivalent mRNA formulations. A model system comprised of mRNA constructs for influenza hemagglutinin and neuraminidase was used to characterize the analytical performance metrics for a VaxArray mRNA assay. The assay presented herein had a time to result of less than 2 hours, required no PCR-based amplification nor extraction of mRNA from lipid nanoparticles, and exhibited high construct specificity that enabled application to the bivalent mixture. The sensitivity for influenza hemagglutinin and neuraminidase mRNA was sub-µg/mL, which is vaccine-relevant, and the average accuracy (%recovery) and precision were 104%±2%and 9%±2%, respectively.

Publisher

Cold Spring Harbor Laboratory

Reference39 articles.

1. The lightning-fast quest for COVID vaccines — and what it means for other diseases;Nature,2020

2. Rapid COVID-19 vaccine development;Science,2020

3. Developing COVID-19 Vaccines. Accessed Aug 29, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/distributing/steps-ensure-safety.html

4. COVID-19 vaccines: rapid development, implications, challenges and future prospects

5. COVID-19 and related vaccine development and research. Mayo Clinic. Accessed Aug 29, 2022. https://www.mayoclinic.org/coronavirus-covid-19/history-disease-outbreaks-vaccine-timeline/covid-19

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3